ID
32986
Beschrijving
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella CRF Seiten: 268-336; 870-938
Trefwoorden
Versies (2)
- 22-11-18 22-11-18 -
- 26-11-18 26-11-18 -
Houder van rechten
GSK group of companies
Geüploaded op
22 november 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Immogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020
Eligibility Criteria
- StudyEvent: ODM
Beschrijving
Eligibility Question
Beschrijving
Did the subject meet all the entry criteria?
Datatype
boolean
Beschrijving
Do not enter the subject into the study if he/she failed any inclusion or exclusion criteria below
Datatype
text
Beschrijving
Inclusion Criteria
Beschrijving
Exclusion Criteria
Beschrijving
tick Yes, if disqualified, tick No, if not disqualified
Datatype
text
Beschrijving
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Datatype
boolean
Beschrijving
For corticosteroids this will mean prednisone, or equivalet, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed
Datatype
boolean
Beschrijving
Planned administration/administration of a vaccine not forseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12)
Datatype
boolean
Beschrijving
Previous vaccination against measles, mumps, rubella and/or varicella
Datatype
boolean
Beschrijving
History of measles, mumps, rubella and/or varicella/zoster diseases
Datatype
boolean
Beschrijving
Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial
Datatype
boolean
Beschrijving
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection
Datatype
boolean
Beschrijving
A family history of congenital or hereditary immunodeficiency
Datatype
boolean
Beschrijving
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
Datatype
boolean
Beschrijving
Major congenital defects or serious chronic illness
Datatype
boolean
Beschrijving
History of any neurologic disorders or seizures
Datatype
boolean
Beschrijving
high-risk persons: new-born infants (0-4 weeks of age); pregnant mother/women with a negative history of chickenpox disease and without recorded vaccination against chickenpox; persons with known immunodeficiency
Datatype
boolean
Beschrijving
The presence of a moderate or severe illness with or without fever. All vaccines cn be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature <37.5°C/ rectal temperature <38°C.
Datatype
boolean
Beschrijving
Rectal temperature >= 38°C or axillary temperature >=37.5°C at the time of vaccination
Datatype
boolean
Beschrijving
Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period
Datatype
boolean
Similar models
Eligibility Criteria
- StudyEvent: ODM
Geen commentaren